Establishment of a cell-based assay system for hepatitis C virus serine protease and its primary applications

World Journal of Gastroenterology

Volumn 9, Issue 11, 2003, Pages 2474-2479

  Mao, Hong Xia ^a   Lan, Shui Yun ^a   Hu, Yun Wen ^a   Xiang, Li ^a   Yuan, Zheng Hong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ALKALINE PHOSPHATASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; CELL ASSAY; CELL STRAIN COS7; CELL STRAIN HEPG2; CELL VIABILITY; CHIMERA; CLONING; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME RELEASE; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; SENSITIVITY AND SPECIFICITY;

EID: 0344899165     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i11.2474     Document Type: Article

References (33)

1. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990; 87: 6547-6549
2. Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, Colletta C, Cariti G, Andreoni M, Biglino A, Calleri G, Maggi G, Tappero GF, Orsi PG, Terreni N, Macor A, Di Napoli A, Rinaldi E, Ciccone G, Rizzetto M. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34: 133-138
3. Kronenberger B, Ruster B, Elez R, Weber S, Piiper A, Lee JH, Roth WK, Zeuzem S. Interferon alfa down-regulates CD81 in patients with chronic hepatitis C. Hepatology 2001; 33: 1518-1526
4. Neddermann P, Tomei L, Steinkuhler C, Gallinari P, Tramontano A, De Francesco R. The nonstructural proteins of the hepatitis C virus: Structure and functions. Biol Chem 1997; 378: 469-476
5. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: Unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 1999; 6: 165-181
6. Lesk AM, Fordham WD. Conservation and variability in the structures of serine proteinases of the chymotrypsin family. J Mol Biol 1996; 258: 501-537
7. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69: 3893-3896
8. Zemel R, Gerechet S, Greif H, Bachmatove L, Birk Y, Golan-Goldhirsh A, Kunin M, Berdichevsky Y, Benhar I, Tur-Kaspa R. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat 2001; 8: 96-102
9. Fujita T, Ishido S, Muramatsu S, Itoh M, Hotta H. Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. Biochem Biophys Res Commun 1996; 229: 825-831
10. Lin X, Yuan ZH, Wu L, Ding JP, Wen YM. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J Virol 2001; 75: 11827-11833
11. Berger J, Hauber J, Hauber R, Geiger R, Cullen BR. Secreted placental alkaline phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 1988; 66: 1-10
12. Nakayama GR, Caton MC, Nova MP, Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 1997; 204: 205-208
13. Kong WH, Zheng G, Lu JN, Tso JK. Temperature dependent expression of cdc2 and cyclin B1 spermatogenic cells during spermatogenesis. Cell Res 2000; 10: 289-302
14. Du GX, Hou LH, Guan RB, Tong YG, Wang HT. Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease. World J Gastroenterol 2002; 8: 1088-1093
15. Kolykhalov AA, Agapov EV, Rice CM. Specificity of the hepatitis C virus NS3 serine protease: Effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol 1994; 68: 7525-7533
16. Bartenschlager R, Ahlborn-Laake L, Yasargil K, Mous J, Jacobsen H. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol 1995; 69: 198-205
17. Bianchi E, Steinkuhler C, Taliani M, Urbani A, Francesco RD, Pessi A. Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease. Anal Biochem 1996; 237: 239-244
18. Steinkuhler C, Urbani A, Tomei L, Biasiol G, Sardana M, Bianchi E, Pessi A, De Francesco R. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol 1996; 70: 6694-6700
19. Pizzi E, Tramontano A, Tomei L, La Monica N, Failla C, Sardana M, Wood T, De Francesco R. Molecular model of the specificity pocket of the hepatitis C virus protease: Implications for substrate recognition. Proc Natl Acad Sci U S A 1994; 91: 888-892
20. Hahm B, Back SH, Lee TG, Wimmer E, Jang SK. Generation of a novel poliovirus with a requirement of the hepatitis C virus protease NS3 activity. Virology 1996; 226: 318-326
21. Cho YG, Moon HS, Sung YC. Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity. J Virol Methods 1997; 65: 201-207
22. Cho YG, Yang SH, Sung YC. In vivo assay for hepatitis C viral serine protease activity using a secreted protein. J Virol Methods 1998; 72: 109-115
23. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67: 2832-2843
24. Komoda Y, Hijikata M, Sato S, Asabe S, Kimura K, Shimotohno K. Substrate requirements of hepatitis C virus serine proteinase for intermolecular polypeptide cleavage in Echerichia coli. J Virol 1994; 68: 7351-7357
25. Heintges T, Encke J, Zu Putlitz J, Wands JR. Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol 2001; 65: 671-680
26. Harvey TJ, Macnaughton TB, Gowans EJ. The development and characterisation of a SV40 T-antigen positive cell line of human hepatic origin. J Virol Methods 1997; 65: 67-74
27. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113
28. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974
29. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516-8523
30. Dentan C, Tselepis AD, Chapman MJ, Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta 1996; 1299: 353-357
31. Angelloz-Nicoud P, Harel L, Binoux M. Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases. Growth Regul 1996; 6: 130-136
32. Hiramatsu N, Ichikawa N, Fukada H, Fujita T, Sullivan CV, Hara A. Identification and characterization of proteases involved in specific proteolysis of vitellogenin and yolk proteins in salmonids. J Exp Zool 2002; 292: 11-25
33. Hahm B, Han DS, Back SH, Song OK, Cho MJ, Kim CJ, Shimotohno K, Jang SK. NS3-4A of hepatitis C virus is a chymotrypsin-like protease. J Virol 1995; 69: 2534-2539